Abstract: The present invention relates to a new manufacture process for producing an iron containing phosphate adsorbent, in particular to a process for manufacturing and isolating an iron(III)-based phosphate adsorbent which exhibits valuable pharmacological properties.

Abstract: The subject invention pertains to materials and methods for stopping or decreasing the blood flow from an open wound or medical or surgical procedure. Compositions of the invention comprise a salt form of a cross-linked polyacrylic acid. In one embodiment, the composition comprises a sodium salt of a polyacrylic acid. Compositions of the invention can also optionally comprise one or more different salt ferrates, and/or a cationic exchanger resins, and/or a silver compound. In an exemplified embodiment, a composition of the invention comprises sodium polyacrylate provided in a dry powdered form. Polyacrylate compositions of the invention can be applied directly to a wound or treatment site, or they can be incorporated into a wound dressing, such as a bandage. The clot or scab formed at a wound or treatment site treated with the present invention is extremely elastic and exhibits considerable tensile strength when stretched to the breaking point.

Abstract: To provide a therapeutic agent and a diagnostic agent for mitochondrial dysfunction brain diseases including cerebral infarction as a representative. A therapeutic agent for a mitochondrial dysfunction brain disease, which comprises (A) ?-aminolevulinic acid represented by the formula (1), a derivative thereof, or a salt thereof and (B) an iron compound in combination. R2R1NCH2COCH2CH2COR3 ??(1) wherein R1 and R2 each independently represents a hydrogen atom, an alkyl group, an acyl group, an alkoxycarbonyl group, an aryl group, or an aralkyl group; and R3 represents a hydroxy group, an alkoxy group, an acyloxy group, an alkoxycarbonyloxy group, an aryloxy group, an aralkyloxy group, or an amino group.

Abstract: Compositions and methods for treating and/or preventing conditions such as diaper rash and atopic dermatitis are disclosed. The compositions and methods are particularly useful in the treatment and prevention of diaper rash and diaper dermatitis caused by the prolonged contact of human skin with body waste. The methods employ the topical application of a trypsin-inhibiting agent to the area in need of such treatment, or the area where prevention is desired. The trypsin-inhibiting agent is preferably a divalent cation/anion pair.

Abstract: The pharmaceutical compositions described comprise a therapeutically effective amount of a ferric compound and at least one bioavailability enhancer for oral delivery. Some pharmaceutical compositions described herein include a suspension which comprises an admixture in solid form of a therapeutically effective amount of a ferric compound and at least one bioavailability enhancer (e.g. a salt of a medium chain fatty acid) and a lipophilic medium. The pharmaceutical compositions may be enteric-coated. Methods of treating or preventing diseases by administering such compositions to affected subjects are also disclosed. The methods of treatment described herein increase the level of iron in the bloodstream of a subject by administering to the subject an effective amount of an oral composition of a ferric iron compound.

Abstract: An embodiment in accordance with the present invention provides a thermo-chemoembolization formulation and method for enhanced interventional image-guided therapy for cancer. The T-C formulation includes magnetic iron oxide nano-particles (MIONs) that heat when exposed to an alternating magnetic field (AMF), a liquid tumorphilic drug carrier that enhances tumor retention of the T-C formulation, and a chemotherapeutic or radiotherapeutic agent. The T-C formulation enhances delivery of heat and chemo- or radio-therapeutic agents with hyperthermia produced by magnetic nanoparticles to improve therapeutic outcomes. The magnetic nanoparticles and tumorphilic drug carrier also allow for multimodal image-guided monitoring of treatment and patient follow-up. The method for enhanced interventional image-guided therapy for cancer includes using an AMF to heat the T-C formulation and activate the thermotherapy.

Abstract: A tissue thickness compensator may generally comprise a first layer comprising a first medicament, a second layer comprising a second medicament, and a third layer comprising a third medicament. The tissue thickness compensator may comprise a first layer comprising a first medicament, a second layer comprising a second medicament, and a reservoir comprising a third medicament disposed within the reservoir. The medicaments may be independently selected from a haemostatic agent, an anti-inflammatory agent, an antibiotic agent, anti-microbial agent, an anti-adhesion agent, an anti-coagulant agent, a pharmaceutically active agent, a matrix metalloproteinase inhibitor, and combinations thereof. Articles of manufacture comprising the tissue thickness compensator and methods of making and using the tissue thickness compensator are also described.

Abstract: There is provided a method of producing a mixed metal compound comprising at least Mg2+ and at least Fe+ having an aluminium content of less than 10000 ppm, having an average crystal size of less than 20 nm (200 A) comprising the steps of: (a) combining a Mg2+ salt and a Fe3+ salt with Na2CO3 and NaOH to produce a slurry, wherein the pH of the slurry is maintained at from 9 5 to 1 1, and wherein the Na2CO3 is provided at an excess of 0 to 4.0 moles than is required to complete the reaction (b) subjecting the slurry to mixing under conditions providing a power per unit volume of 0 03 to 1.6 kW/m3 (c) separating the mixed metal compound from the slurry, to obtain a crude product having a dry solid content of at least 10 wt % (d) drying the crude product either by (i) heating the crude product to a temperature of no greater than 150° C. and sufficient to provide a water evaporation rate of 0.

Abstract: The present invention generally relates to orally administered pharmaceutical compositions of iron compounds with medium chain fatty acid salts. The invention further relates to methods of using the pharmaceutical compositions to treat iron deficiency and related disorders.

Abstract: The present invention relates to a system comprising magnetic nanoparticles of a metal oxide and a polymer, which in turn contains monomers with different functional groups. This system can be solid (nanocomposite) or liquid (ferrofluid). The present invention also relates to a process for obtaining the system, as well as its use, mainly in biotechnological, veterinary and medical applications, such as, for example, for the diagnosis and treatment of human diseases.

Abstract: An antimicrobial and chemical deactivating composition for use in a liquid medium or for incorporation into a coating, structural plastic materials, thin microporous membranes, textiles and sponges. The composition includes macrosize or submicron particles of silver, platinum with silver and their salts with parabens, oxide, salicylate, acetate, citrate, benzoate and phosphate along with copper and zinc salts of the same.

Abstract: This invention relates to high surface area materials, such as nanoparticles, that are coated with metal ions. These modified nanoparticles have active sites that bind various gases and/or odorous compounds, thereby removing these compounds from a medium such as air or water. Metal ions are adsorbed onto the surface of the nanoparticle and bound strongly to the surface. By selection of the metal ion, specific gaseous compounds and/or odorous compounds can be targeted and removed efficiently and effectively from both aqueous phase and from the air. The modified nanoparticles are useful in numerous article of manufacture for industrial and consumer use.

Abstract: The present invention provides agents for preventing, improving or treating phosphorus-related disorders and oral preparations; agents high in biosafety and phosphorus adsorptive power, which contain, as an active ingredient, ferric hydroxide as produced under such conditions that a ferrous species is present.

Abstract: A substance for use as a medicament, comprises a solid mixed metal compound of formula (I): MII1-aMIIIaObAn?c.zH2O (I) where MII is at least one bivalent metal: MIII bis at least one trivalent metal; An? is at least one n-valent anion; 2+a=2b+?cn; and ?cn<0.9a. The substance may be made by heating at a temperature of from 200° C. to 600° C., preferably from 250° C. to 500° C. of a substance comprising a compound of formula (II): MII1-xMIIIx(OH)2An?y.mH2O (II) where MII is at least one bivalent metal; MIII is at least one trivalent metal; An? is at least one n-valent anion; x=?yn 0<x?0.5, 0<y?1 and 0<m?10.

Abstract: The present invention relates to a pearl pigment obtained by coating the surface of a flaky powder with a colored metal or a colored metal oxide and further coating the surface of the above colored metal- or colored metal oxide-coated flaky powder with a colorless metal or a colorless metal oxide, wherein when the pearl pigment is applied onto the surface of black artificial leather in an average amount of 0.05 mg/cm2 and the intensity of light reflected from the pearl pigment is measured using illuminant C at a 2° viewing angle with a spectrophotometric colorimeter which is provided with a sheet polarizer S on the light incident side and a sheet polarizer P on the light receiving side, the powder reflection light which is incident to the pearl pigment as a measurement sample at an angle of 45° to the direction normal to the surface of the sample and is received in the direction normal to the surface of the sample has absolute values a* and b* of 10 or less, and make-up cosmetics containing the pearl pigment.

Abstract: Subject of the present invention are compositions comprising a mixture of calcium, magnesium and iron salts for use as a pharmaceutical preparation for adsorbing phosphate, especially for use as pharmaceutical preparations for the treatment of hyperphosphataemia, chronic kidney deficiency as well as for the treatment of haemodialysis patients.

Abstract: Disclosed are compositions comprising an effective amount of a zinc containing material having an aqueous solubility within the composition of less than about 25% by weight at 25° C.; from about 5% to about 50% of a surfactant; and from about 40% to about 95% water; wherein the pH of the composition is greater than about 7. Further disclosed are compositions comprising an effective amount of a zinc containing material having an aqueous solubility within the composition of less than about 25% by weight at 25° C.; from about 5% to about 50% of a surfactant; and from about 0.1% to about 5% of a zinc ionophoric material; from about 40% to about 95% water; and wherein the pH of the composition is greater than about 7.

Abstract: The present invention provides a pharmaceutical composition for dehydrating, atrophying and eliminating pathological tissues comprising inorganic polymeric ferric salt and/or inorganic polymeric ferric salt composite as its active ingredients, in which the inorganic polymeric ferric salt is polyferric sulfate, and the inorganic polymeric ferric salt composite is selected from a group consisting of poly-silicate ferric salts, polyphosphate ferric salts and their analogue. A surprising medical effect can be reached by treating pathological tissues with the pharmaceutical composition of the present invention which will make the treated pathological tissues dehydrated, atrophied, and absorbed or sloughed off.

Abstract: There is provided a dissolvable film polymer matrix that includes a plurality of magnetically responsive kertin-like fibers for application to an individual's face or head. The dissolvable film polymer matrix product includes hairs that are magnetically oriented in a non-random plain to be applied on an individuals face or head to simulate the appearance of the individual's natural hair. Methods of manufacturing and applying the dissolvable polymer matrix product are also disclosed.

Abstract: The present invention provides a pharmaceutical composition for dehydrating and atrophying pathological tissues comprising ferric subsulfate, polyferric sulfate or a mixture thereof is disclosed. Ferric subsulfate and polyferric sulfate are traditionally used as water treatment agent. The inventor surprisingly discovered the medical value of these substances. The compositions are cost-effective, convenient to use and have significant effects in treatment of vascular diseases such as hemorrhoids, hemangiomas, hematomas (including hematomas caused by brain hemorrhage), thrombi and varices, and topical traumas such as bleeding and edemas. The compositions are also capable of killing various tumor cells by targeted injection.

Abstract: Methods of treating animal litter and/or bedding material for control of volatile ammonia and soluble phosphorous include applying granular partially hydrated ferric sulfate to the litter. The partially hydrated ferric sulfate ranges from gray to tan in color and is spread onto the litter at a rate effective to reduce ammonia volatilization and reduce soluble phosphorous. Relative to reagent grade ferric sulfate, the partially hydrated ferric sulfate exhibits lower hygroscopicity and higher deliquescence. The ferric sulfate is prepared by a process comprising oxidizing ferrous sulfate with sulfuric acid using a molecular oxygen oxidizing agent at an elevated pressure relative to atmospheric and at a temperature of 60° C. to 140° C. to produce a gray to tan colored granular product.

Abstract: The invention provides a mineral complex comprising about 40 wt. % to about 60 wt. % SiO2, about 6 wt. % to about 16 wt. % Fe2O3, about 4 wt. % to about 12 wt. %. CaO, and about 2 wt. % to about 8 wt. % MgO. The invention also provides animal feeds comprising the mineral complex. Methods for increasing the feed efficiency and weight gain in an animal by administering the mineral complex or an animal feed comprising the mineral complex also are provided.

Abstract: The invention provides a mineral complex comprising about 40 wt. % to about 60 wt. % SiO2, about 6 wt. % to about 16 wt. % Fe2O3, about 4 wt. % to about 12 wt. %. CaO, and about 2 wt. % to about 8 wt. % MgO. The invention also provides animal feeds comprising the mineral complex. Methods for increasing the feed efficiency and weight gain in an animal by administering the mineral complex or an animal feed comprising the mineral complex also are provided.

Abstract: The invention provides a mineral complex comprising about 40 wt. % to about 60 wt. % SiO2, about 6 wt. % to about 16 wt. % Fe2O3, about 4 wt. % to about 12 wt. %. CaO, and about 2 wt. % to about 8 wt. % MgO. The invention also provides animal feeds comprising the mineral complex. Methods for increasing the feed efficiency and weight gain in an animal by administering the mineral complex or an animal feed comprising the mineral complex also are provided.

Abstract: The subject of the present invention is to provide a bioactivator which is useful as a medicine, growth promoting agent for plants and animals, and the like, wherein the bioactive effectiveness of a ferric salt is reinforced and stabilized. One or more kind of vitamin selected from a group consisting of vitamins C, E and K is (are) added to a ferric salt as an anti-oxidizing and bioactivity reinforcing agent, with a magnesium salt being further added as a stabilizer.

Abstract: The present invention relates to a pearl pigment obtained by coating the surface of a flaky powder with a colored metal or a colored metal oxide and further coating the surface of the above colored metal- or colored metal oxide-coated flaky powder with a colorless metal or a colorless metal oxide, wherein when the pearl pigment is applied onto the surface of black artificial leather in an average amount of 0.05 mg/cm2 and the intensity of light reflected from the pearl pigment is measured using illuminant C at a 2° viewing angle with a spectrophotometric colorimeter which is provided with a sheet polarizer S on the light incident side and a sheet polarizer P on the light receiving side, the powder reflection light which is incident to the pearl pigment as a measurement sample at an angle of 45° to the direction normal to the surface of the sample and is received in the direction normal to the surface of the sample has absolute values a* and b* of 10 or less, and make-up cosmetics containing the pearl pigment.

Abstract: The present invention relates to a method for preparing a ferrite superparamagnetic nano particle engineered by magnesium doping, and a technique for applying it to hyperthermia cancer cell treatment and the heat shock protein (HSP) self-defense mechanism.

Abstract: The present disclosure relates to nanoparticle-containing implantable and preferably biodegradable medical products and their use for the thermotherapeutic after-treatment after surgical removal of tumors and cancerous ulcers.

Abstract: Bait compositions of spinosyns in combination with metal complexones and other mollusicides are provided in an environmentally safe composition that is effective to a treat and/or control a wide spectrum of insect and mollusc pests.

Abstract: The present invention relates to a method of treating osteoarthritis by administering a mineral composition in the form of a nutritional supplement, where the mineral composition may contain Smectite, Gypsum, Quartz, Feldspar, Jarosite, Kaolinite and/or Zeolite.

Abstract: The present invention provides an environmentally compatible, pesticidal composition and method for the control of insect pests. The composition includes two components. The first component is a chelating agent, a metal complex of a chelating agent, and mixtures thereof, and the second component is preferably a carrier material.

Abstract: The present invention provides an environmentally compatible, pesticidal composition and method for the control of insect pests. The composition includes two components. The first component is a chelating agent, a metal complex of a chelating agent, and mixtures thereof, and the second component is preferably a carrier material.

Abstract: The present invention provides a method for preventing or repairing damage to a fetal membrane. In one embodiment, the method comprises contacting a fetal membrane with a composition comprising a four-armed catechol-terminated polyethylene glycol (cPEG) and a biocompatible oxidant. In one embodiment, the four-armed cPEG and the biocompatible oxidant are initially contained in separate solutions, and the solutions are mixed to form the composition just prior to or at the same time that the composition contacts the fetal membrane.

Abstract: This invention discloses the use of an E-selectin antagonist and a mobilizer of hematopoietic stem cells or progenitor cells in methods and compositions for treating or preventing immunocompromised conditions resulting from medical treatment. The present invention is particular relevant for prophylaxis and/or treatment of hematopoeitic disorders including neutropenia, agranulocytosis, anemia and thrombocytopenia in individuals receiving or proposed to receive treatments that target rapidly dividing cells or that disrupt the cell cycle or cell division.

Abstract: A mixed metal compound for pharmaceutical use is free from aluminium and has a phosphate binding capacity of at least 30%, by weight of the total weight of phosphate present, over a pH range of from 2-8. The compound is especially useful for treatment of hyperphosphataemia. The metals are preferably iron (III) and at least one of calcium, magnesium, lanthanum and cerium. A metal sulphate for pharmaceutical use is selected from at least one of calcium, lanthanum and cerium sulphate compounds and has a phosphate binding capacity of at least 30% by weight of the total phosphate present, over a pH range from 2-8.

Abstract: This invention discloses the use of an E-selectin antagonist in methods and compositions for treating or preventing immunocompromised conditions resulting from medical treatment. The present invention is particular useful for prophylaxis and/or treatment of hematopoietic disorders including neutropenia, agranulocytosis, anemia and thrombocytopenia in individuals receiving or proposed to receive treatments that target rapidly dividing cells or that disrupt the cell cycle or cell division.

Abstract: A stable packaged bicarbonate solution for use in dialysis treatment and for treating anemia, iron deficiency, or reducing the required dose of recombinant erythropoietin to treat anemia includes a bicarbonate solution into which ferric pyrophosphate is dissolved. The amount of ferric pyrophosphate dissolved in the bicarbonate solution is sufficient to provide a therapeutic effect for the treatment of anemia, iron deficiency or to reduce dose of recombinant erythropoietin needed to treat anemia when the bicarbonate solution is combined with other dialysis components to form a dialysate used for dialyzing a patient. The ferric pyrophosphate is stabilized in the bicarbonate solution by holding the solution in a polyolefin container or container liner, such as a high density polyethylene container or liner.

Abstract: Pest controlling compositions exhibiting enhanced pesticidal activity levels are disclosed. In one embodiment, a composition includes at least one pesticide and at least one metal oxide. In this embodiment, the composition exhibits enhanced pesticidal activity levels compared to a composition dissimilar only in not having the at least one metal oxide. Still, other alternative embodiment pesticide compositions exhibiting enhanced pesticidal activity are disclosed.

Abstract: Pest controlling compositions exhibiting enhanced pesticidal activity levels are disclosed. In one embodiment, a composition includes at least one pesticide, at least one transition metal salt and at least one proteinaceous material. In this embodiment, the composition exhibits enhanced pesticidal activity levels compared to a composition dissimilar only in not having the at least one transition metal salt and the at least one proteinaceous material.

Abstract: Hypoallergenic metal amino acid chelate compositions, hypoallergenic formulations containing hypoallergenic metal amino acid chelates, methods of preparing hypoallergenic metal amino acid chelate, and methods of administering hypoallergenic metal amino acid chelates are provided. Specifically, the present invention provides metal amino acid chelates that are substantially free of allergens such that administration of the metal amino acid chelates to a subject in an effective amount to cause a medicinal or nutritional result does not produce a discernable adverse allergic reaction. The metal amino acid chelates can include chelates having a naturally occurring amino acid to metal molar ratio of from about 1:1 to 4:1.

Abstract: Compositions comprising a gel system made from a combination of a fractal network of nanoparticles and translucent macroscopic particles, titanium dioxide and other color pigments is disclosed. The compositions are capable of forming an effective film on the biological surface such as skin to blurring fine lines and wrinkles while retaining a natural look of the skin as a consequence of synergy between the fractal particles, the macroscopic particles, titanium dioxide and color pigments. Also disclosed methods for their use.

Abstract: Pharmaceutical compositions for oral administration, in particular administration as an oral delivery system to be swallowed directly or capable of disintegration in the oral cavity, comprising iron oxy-hydroxide in high loading.

Abstract: A mixed metal compound for pharmaceutical use is free from aluminium and has a phosphate binding capacity of at least 30%, by weight of the total weight of phosphate present, over a pH range of from 2-8. The compound is especially useful for treatment of hyperphosphataemia. The metals are preferably iron (III) and at least one of calcium, magnesium, lanthanum and cerium. A metal sulphate for pharmaceutical use is selected from at least one of calcium, lanthanum and cerium sulphate compounds and has a phosphate binding capacity of at least 30% by weight of the total phosphate present, over a pH range from 2-8.

Abstract: The present invention relates to nanoparticle composition comprising cellulose nanofibers embedded with nanosized material. More particularly the present invention relates to cellulose nanofibers embedded with silver or iron oxide embedded silver. In addition the present invention is also related to the preparation of the cellulose nanofibers embedded with nanosized material. The nanoparticle composition is antibacterial in nature and can be utilized in various antibacterial applications.

Abstract: A herbomineral composition for the treatment of sickle cell disease is described in the present invention. The herbo mineral composition include some herbal ingredients such as Jaiphal, Sunthi, Jivanti, Haritaki, Guduchi, Shatavari, Dadima, Pippali, along with the therapeutic minerals such as Abrakha Bhasma and Loha Bhasma at suitable concentrations to obtain synergistic anti sickling activity. The composition exhibited up to 60-87% antisickling activity on RBCs in ‘vitro’ at various concentrations. Patients treated with this composition found relief from most of the severe symptoms of sickle cell disease and sickle cell anemia, and had excellent improvement in quality of life.

Abstract: Chronic obstructive airway diseases are treated by administering an osmotically active compound such as a salt, sugar, sugar alcohol, or organic osmolyte to the afflicted airway surface. The compound may be administered as a liquid or dry powder aerosol formulation. Diseases that can be treated by the method include cystic fibrosis, chronic bronchitis, and ciliary dyskinesia. The formulations of the invention can also be used in conjunction with other active agents such as bronchodilators, sodium channel blockers, antibiotics, enzymes, or purinoceptor agonists on airway surfaces.

Abstract: A method of selecting or determining a candidate compound suitable for use as a phosphate binder is disclosed. The candidate compound includes ferric compounds, ferric compound complexes, and their derivatives, salts, analogs, and metabolites. The effectiveness of the candidate compound as a phosphate binder is evaluated by a method, comprising measuring and correlating reduction of phosphate concentration in solution and reduction of phosphate absorption in cells.

Abstract: Formulations and blends are described comprising zinc, silver, bismuth and copper in non-toxic amounts that are useful as treatments of a wide variety of conditions and diseases promoted by bacteria or other microorganisms.

Abstract: The present invention describes therapeutic compositions comprising one or more minerals, including trivalent iron, divalent manganese and salts thereof, suitable in facilitating synthesis and deposition of connective tissue matrix, particularly rich of elastin and collagen, and mitogenic potential in human dermal fibroblasts. It also describes the phenomenon in which stimulation of elastogenesis by arterial SMC associates with a net decrease in proliferation of these cell types. The present invention also describes methods of treatment of human skin fibroblasts and arterial smooth muscle cells. The therapeutic compositions of the present invention comprise one or more of trivalent iron or divalent manganese or salts thereof and may be combined with an elastic tissue digest.

Abstract: A present invention relate to a diethylenetriaminepentaacetic acid (DTPA)-modified ferrofluid and a preparation method of the same. The DTPA-ferrofluid contains DTPA and a nano ferrofluid. The DTPA-ferrofluid can be further mixed with a peptide. Unmodified or modified peptide ferrofluids prepared from the DTPA-modified ferrofluid, such as unmodified or modified octreotide-containing or unmodified or modified lanreotide-containing ferrofluid.